Definition
The maintenance dose is the dose you stay on once titration ends, such as Wegovy 1.7 or 2.4 mg weekly or Zepbound 5, 10 or 15 mg weekly. The highest dose is not the goal for everyone. The labels say to weigh response and tolerability.
Each label names its own maintenance doses. For weight reduction, Wegovy injection is 1.7 mg or 2.4 mg (recommended) once a week, and adults who tolerate 2.4 mg for at least 4 weeks may go to 7.2 mg if more weight loss is needed. Wegovy tablets are 25 mg a day. Zepbound is 5, 10 or 15 mg a week. Ozempic, for type 2 diabetes, is 0.5, 1 or 2 mg a week. Foundayo does not use the word maintenance; the label allows steps to 9, 14.5 or 17.2 mg based on response and tolerability.
Staying on treatment matters for keeping weight off. In a Zepbound withdrawal trial, adults who kept taking it after 36 weeks lost another 5.5% of body weight by week 88, while those switched to placebo regained 14.0%. Side effects usually ease once the dose stops changing, though some people notice nausea or food noise return months in.
Your prescriber may also lower the dose if side effects do not settle. At GLP-1 SOS we see maintenance as the long road, where daily habits, protein and gut comfort matter more than the number on the pen. For how you got there, see dose titration.
In the Lab
- Is a plateau normal on a GLP-1 (and when)?
- Why did my GLP-1 stop working?
- Why GLP-1 nausea comes back months in
- Why you may feel “not normal” months after quitting a GLP-1
From the people behind the Lab
You do not have to figure this out alone.
GLP-1 SOS is the daily companion made for life on a GLP-1. Plain answers like this one, a support team that replies to real questions from real people, and daily formulas like GLP-1 SOS Daily Gut Relief, designed around the side effects that come with the medication. The GLP-1 Lab is our free education arm: no login, no paywall, no hype. Side effects are part of the road. Suffering through them is not.
Sources (4)
- Wegovy (semaglutide) injection and tablets, Prescribing Information. Novo Nordisk / FDA, revised June 2026.
- Zepbound (tirzepatide) injection, Prescribing Information. Eli Lilly, revised August 2026.
- Foundayo (orforglipron) tablets, Prescribing Information. Eli Lilly, revised July 2026.
- Ozempic (semaglutide) injection, Prescribing Information. Novo Nordisk, revised May 2026.
Reviewed by the GLP-1 SOS editorial team · Education, not medical advice · Talk to your prescriber about your dose and your symptoms.
